Jubilant Pharmova · NSE: JUBLPHARMA · BSE: 530019
Q1 FY24 results · Apr–Jun 2023
Jubilant Pharmova reported revenue from operations of ₹1,586.90 crore (up 10.2% from Q1 FY23) and net profit of ₹6.00 crore (down 87.2% from Q1 FY23) for Q1 FY24 (Apr–Jun 2023), on a consolidated basis.
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,586.90 | 1,440.47 | +10.2% | 1,678.00 | −5.4% |
| Other income | 8.60 | 22.56 | −61.9% | 4.45 | +93.3% |
| Total income | 1,595.50 | 1,463.03 | +9.1% | 1,682.45 | −5.2% |
| Profit before share of associates & JVs and tax | 26.60 | 69.21 | −61.6% | (103.12) | Turned profit |
| Share of profit/(loss) of associates & JVs | (1.40) | (0.15) | 16.71 | ||
| Net profit for the period | 6.00 | 46.75 | −87.2% | (100.51) | Turned profit |
| Attributable to shareholders of the company | 6.40 | 47.04 | −86.4% | (97.84) | Turned profit |
| EPS, basic (₹) | 0.40 | 2.96 | −86.5% | (6.15) | Turned profit |
| Net margin (%) | 0.4 | 3.2 | -6.0 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 217.40 | 200.04 | +8.7% | 199.84 | +8.8% |
| Other income | 15.90 | 14.77 | +7.7% | 13.66 | +16.4% |
| Total income | 233.30 | 214.81 | +8.6% | 213.50 | +9.3% |
| Profit before tax | 2.30 | (6.49) | Turned profit | (1.23) | Turned profit |
| Net profit for the period | 1.90 | (5.18) | Turned profit | (30.86) | Turned profit |
| EPS, basic (₹) | 0.12 | (0.33) | Turned profit | (1.94) | Turned profit |
| Net margin (%) | 0.9 | -2.6 | -15.4 |
Consolidated
- Filed with BSE
- 20 Jul 2023, 12:56 IST
- Board meeting
- 19 Jul 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 20 Jul 2023, 12:56 IST
- Board meeting
- 19 Jul 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE